Hidradenitis Suppurativa Written Action Plan

Evaluating the Effect of a Written Action Plan on Comfort and Understanding of Hidradenitis Suppurativa

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04230291

Acronym

HSWAP

Enrollment

Registered

2020-01-18

Start date

2020-02-01

Completion date

2020-03-17

Last updated

2020-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hidradenitis Suppurativa

Brief summary

This study is being conducted to evaluate if a written action plan for hidradenitis suppurativa (HS) will help patients with hidradenitis suppurativa gain a better understanding of the condition and how to manage the condition on a daily basis compared to a routine verbal consultation.

Interventions

BEHAVIORALVerbal consultation

Verbal consultation only without written information before receiving written action plan

BEHAVIORALWritten Action Plan

Written handout of treatment plan and disease management strategies

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Has a diagnosis of HS

Exclusion criteria

* Has been exposed to a written action plan for HS before

Design outcomes

Primary

Measure	Time frame	Description
Visits to high-cost care settings	12 months	Number of visits to ER, urgent care, or hospitalizations because of HS

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026